Mayne Pharma Group Ltd (MYX)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013184)
◆英語タイトル:Mayne Pharma Group Ltd (MYX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013184
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:58
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Mayne Pharma Group Ltd (Mayne Pharma), formerly Mayne Pharma International Pty Ltd, a subsidiary of Hospira Inc, is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company’s products comprise astrix capsules and tablets, erymax capsules, kapanol capsules, doryx capsules, magnoplasm, and lozanoc and itragerm capsules. It offers services which include product development, analytical development, contract manufacturing, formulation development, logistics, and others. Mayne Pharma offers products in the dosage forms of powders, liquids, tablets, capsules, and creams. The company operates manufacturing facilities in Australia and the US. Mayne Pharma is headquartered in Melbourne, Victoria, Australia.

Mayne Pharma Group Ltd (MYX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Mayne Pharma Group Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 13
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 14
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 16
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 17
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 18
Partnerships 19
Mayne Pharma Enters into Distribution Agreement with IDT Australia 19
Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 20
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 22
Licensing Agreements 24
HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 24
HedgePath Pharma Enters Into Licensing Agreement With Mayne Pharma 25
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 27
Equity Offering 28
Mayne Pharma to Raise USD444.5 Million in Rights Offering of Shares 28
Mayne Pharma to Raise USD212 Million in Private Placement of Shares 30
HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 32
HedgePath Pharma Raises USD2.5 Million in Private Placement of Shares and Warrants 33
Mayne Pharma Completes Private Placement Of Shares For US$16 Million 34
Mayne Pharma Group Completes Private Placement Of Shares For US$5 Million 35
Mayne Pharma Group Completes Private Placement Of Shares For US$0.14 Million 36
Mayne Pharma Group Completes Private Placement Of Shares For US$19 Million 37
Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For US$4 Million 39
Acquisition 40
Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 40
Mayne Pharma Completes Acquisition Of Metrics For Up To US$120 Million 41
Metrics Acquires Midlothian Labs From Hi-Tech Pharmacal 43
Mayne Pharma Group Ltd – Key Competitors 44
Mayne Pharma Group Ltd – Key Employees 45
Mayne Pharma Group Ltd – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 48
Corporate Communications 48
Mar 09, 2017: Mayne Pharma appoints new Group CFO and Company Secretary 48
Jan 16, 2017: Mayne Pharma Announces Leadership Changes 49
Sep 21, 2016: Mayne Pharma Appoints New Director 50
Legal and Regulatory 51
Jul 29, 2016: Mayne Pharma Announces Settlement From Patent Infringement Case 51
Product Approvals 52
Jun 02, 2016: FDA Grants Orphan Drug Designation to SUBA-Itraconazole for Treatment of Patients with BCCNS 52
Clinical Trials 53
May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update 53
Oct 20, 2016: HedgePath Pharmaceuticals Announces Further Positive Interim Data in its Phase II(b) Cancer Trial 54
Aug 03, 2016: HedgePath Pharmaceuticals Announces Positive Interim Data in its Phase II(b) Cancer Trial 56
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Mayne Pharma Group Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Mayne Pharma Group Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 13
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 14
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 16
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 17
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 18
Mayne Pharma Enters into Distribution Agreement with IDT Australia 19
Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 20
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 22
HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 24
HedgePath Pharma Enters Into Licensing Agreement With Mayne Pharma 25
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 27
Mayne Pharma to Raise USD444.5 Million in Rights Offering of Shares 28
Mayne Pharma to Raise USD212 Million in Private Placement of Shares 30
HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 32
HedgePath Pharma Raises USD2.5 Million in Private Placement of Shares and Warrants 33
Mayne Pharma Completes Private Placement Of Shares For US$16 Million 34
Mayne Pharma Group Completes Private Placement Of Shares For US$5 Million 35
Mayne Pharma Group Completes Private Placement Of Shares For US$0.14 Million 36
Mayne Pharma Group Completes Private Placement Of Shares For US$19 Million 37
Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For US$4 Million 39
Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 40
Mayne Pharma Completes Acquisition Of Metrics For Up To US$120 Million 41
Metrics Acquires Midlothian Labs From Hi-Tech Pharmacal 43
Mayne Pharma Group Ltd, Key Competitors 44
Mayne Pharma Group Ltd, Key Employees 45
Mayne Pharma Group Ltd, Other Locations 46
Mayne Pharma Group Ltd, Subsidiaries 46

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Mayne Pharma Group Ltd (MYX)-製薬・医療分野:企業M&A・提携分析(Mayne Pharma Group Ltd (MYX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆